Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases, has announced that the first patient has been dosed in its phase 1/2 trial evaluating EO4010.
Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, has closed a $10 million Series A financing round, led by Mercia.
AstraZeneca has shared updated results from a recent phase 3 clinical trial of its Imfinzi (durvalumab) plus Imjudo (tremelimumab) treatment plan in certain patients with hepatocellular carcinoma (HCC), the most common type of liver cancer.
PrecisionLife, a techbio company driving precision medicine in complex chronic diseases, has announced a data access agreement with the University of Oxford to spearhead new treatments for endometriosis.
Donaldson, a provider of filtration products and solutions, has acquired Univercells Technologies, a producer of biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing, to broaden its life sciences reach....
Astraveus, the creator of modular, microfluidic cell foundries for cell and gene therapy (CGT) manufacturing, has raised €16.5 million in series seed financing.
A microbiome therapeutic developed by the Danish biotech company Freya Biosciences has achieved promising topline results in a phase 1 trial in women with asymptomatic vaginal tract dysbiosis.
Dr. Theresa Heah is the CEO of Intergalactic Therapeutics, bringing over two decades of global leadership experience in ophthalmology drug development along with commercialization in early-stage, private-staged companies. We spoke to her about her background,...
Unquestionably, the buzzword of 2023 is artificial intelligence (AI). From ChatGPT-4 preparing to revolutionize online research to IBM’s project debater engaging humans in live debates, it’s clear that we stand at the dawn of a new era of assistive and...
SMi Systems, a company specializing in single molecule imaging and quantification technologies, has disclosed a £6m seed funding round to develop the utility of a novel multi-omic platform for in vitro diagnosis and biomedical research.
New research reveals the bioavailability of both CBD and THC components of hemp, is higher when delivered in certain oil carriers, and describes how some CBD is converted into THC in the body.
Sphere Fluidics, a company developing single cell analysis systems, has announced that Biosyntia, a biotech company focused on synthetic biology and metabolic engineering, has adopted its Pico-Mine platform within its workflows.
Mimetas, a biotech company developing human organ-on-a-chip tissue models and products for drug development, has expanded its ongoing partnership with global pharmaceutical company Astellas, to include automation and application support.
Amgen has announced that the US Food and Drug administration (FDA) has converted the accelerated approval for its blood cancer treatment Blincyto to a full approval.
Vial, a CRO providing clinical trial management services, has partnered with biopharma company Nielsen BioSciences to study the safety and efficacy of CANDIN, a treatment for common warts.
Oliva Therapeutics, a healthcare company focused on product commercialization, sales, marketing, distribution, and promotion, has announced its new long-term partnership with Rio Biopharmaceuticals, for the exclusive North American supply and distribution...
Kelly Smeltzer loves processes, processes that work and save on waste and money. She has a particular interest in the excess production of pharmaceutical drugs and wastage, with 30 years of experience in supply chain management under her belt.
Saudi Arabia’s Public Investment Fund (PIF) has launched a new commercial-scale contract development and manufacturing organization (CDMO) called Lifera.
Vera Therapeutics, a late-stage biotech company focused on developing treatments for patients with serious immunological diseases, has announced the results of its phase 2 clinical trial of atacicept for the treatment of IgA nephropathy (IgAN).
CStone Pharmaceuticals' shares have risen after academic journal Nature Cancer published the clinical study results of its lung-cancer treatment sugemalimab.
SCTbio, a contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors, has partnered with cell and regenerative medicine specialist Cyto-care.
Eli Lilly’s blockbuster type 2 diabetes (T2B) drug Mounjaro is likely to become the dominant therapy in obesity and T2D, due to significant weight loss induced by it, says GlobalData.
As the global contract development and manufacturing organization (CDMO) market continues to grow, we caught up with Federico Pollano, SVP business development at Rentschler Biopharma, at Bio International 2023, to discuss the company's ongoing growth...
A-Alpha Bio, a synthetic biology and machine learning company, has announced its collaboration with Gilead that aims to advance the design of human immunodeficiency virus (HIV) therapies.
Katherine Vega Stultz is the CEO and president of Ocelot Bio, a clinical-stage biotech company focused on the development of therapeutics to treat complications of end-stage liver disease.
With both GSK and Pfizer recently gaining FDA approval for their respective respiratory syncytial virus (RSV) vaccines, the stakes are high for competition in the sector.
Following its latest funding round, Rosa Biotech has announced plans to accelerate development of its bio-sensing technology, designed to enable cost effective screening of a range of diseases with high accuracy at an early stage.
Sygnature Discovery has launched an in vivo inflammation model, that the company says is ‘exciting but only the beginning’ of understanding life-limiting neuroinflammatory conditions.
Shionogi has enrolled the first participant in Japan in its phase 3 clinical trial of oral antiviral ensitrelvir to stop the post-infection progression of Covid-19.
Syncona has launched Beacon Therapeutics, a new ophthalmic gene therapy company with a purpose to restore and improve the vision of patients with retinal diseases, with £96 million Series A financing.
Launching in April last year, Cancer Research Horizons (CRH) describes itself as the “meeting point” between academia and industry, attempting to prevent drug discoveries from entering the ‘valley of death’ and stalling in their progress.
Axol Bioscience Ltd, a pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.
Adede is a seasoned computer scientist and data professional known for providing high quality service whilst employing her multi talents which include efficiency, analytical thinking, and fast learning.
Adede is a seasoned computer scientist and data professional known for providing high quality service whilst employing her multi talents which include efficiency, analytical thinking, and fast learning.
Veeva has announced the expansion of its business consulting services to help life sciences organizations achieve “greater speed and efficiency” across the product development lifecycle.
Back in May, Cytiva completed its integration with Pall Life Sciences, a move that CEO Emmanuel Ligner now describes as a “winning recipe” which has improved the company’s supply chain and fostered industry collaboration.
Samsung Biologics’ upcoming fifth plant will be operational by April 2025, five months earlier than previously expected, the biotech company revealed at BIO International Convention on Monday 5.
CDMO Wheeler Bio, Inc. has welcomed Charles River’s flexible biologics testing lab, RightSource, to its Oklahoma City drug substance manufacturing site.
Providence Therapeutics, a biopharmaceutical company developing mRNA vaccines and therapeutics, has announced its partnership with University Health Network (UHN).
BenevolentAI, a clinical-stage AI development company, has announced the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.
Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).
Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs. $2.5 billion in 2022, with just under 70% stemming from the US, according to a report from Bloomberg Intelligence.
